Celldex Therapeutics (CLDX) news
Recent news
CellDex Therapeutics shares fall 1.9% after data from late-stage trials of its skin disease drug
AInvest Wire · Sep 22, 2026CellDex Therapeutics shares reverse course; last down 19.2% premarket
CellDex Therapeutics Inc. (NASDAQ: CDXT) shares fell 19.2% in premarket trading on September 22, 2026, following the release of updated data from its Phase 2 clinical trial for the treatment of multiple myeloma. The data showed mixed results, with some patients experiencing a partial response but…
AInvest Wire · Sep 22, 2026CellDex shares extend losses to hit session low of 42%
AInvest Wire · Sep 22, 2026CellDex shares jump 9.5% after positive trial results
AInvest Wire · Sep 22, 2026CellDex's phase 3 Barzalovimab trials met endpoints
Celldex Therapeutics has announced that its phase 3 Barzalovimab trials have met their primary endpoints, marking a significant milestone in the company’s clinical development pipeline. The results indicate that the investigational therapy achieved statistically significant outcomes compared to the…
AInvest Wire · Sep 22, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.